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The amyloid precursor protein (APP) is proteolytically processed by b- and c-secretases to release
amyloid-b peptide (Ab), the main component found in senile plaques of Alzheimer’s disease (AD)
patient brains. Alternatively, APP can be cleaved within the Ab sequence by a-secretase, thus pre-
cluding the generation of Ab. We have demonstrated that activation of the P2X7 receptor leads to
a reduction of a-secretase activity in Neuro-2a cells. Moreover, the P2X7 ligand 20(30)-O-(4-ben-
zoylbenzoyl) ATP (BzATP) can also activate a different P2 receptor in these cells. This receptor, whose
pharmacology resembles that of the P2Y2 receptor, has an opposite effect, leading to increases in a-
secretase activity. Our study suggests that P2X7R and P2Y2R could be novel therapeutic targets in
AD.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction families: a P2X family of ligand-gated ion channels and a P2Y fam-Alzheimer’s disease (AD) is a progressive dementia character-
ized by extracellular deposits of amyloid-b peptide (Ab) in senile
plaques and intracellular neuroﬁbrillary tangles comprising hyper-
phosphorylated tau assemblies. Ab is produced when the amyloid
precursor protein (APP) is sequentially cleaved by b- and c-secre-
tases [1]. There is also a non-Ab-forming pathway in cells involving
a-secretase. The a-secretase cleaves APP within the Ab sequence,
thereby precluding the formation of neurotoxic Ab [2]. Several en-
zymes capable of mediating non-amyloidogenic a-processing of
APP have been identiﬁed [3].
P2 nucleotide receptors modulate a wide range of physiological
responses in neural tissues. These receptors belong to two majorchemical Societies. Published by E
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d Complutense de Madrid,ily of G protein-coupled receptors [4]. The G-protein coupled P2Y2
receptor has been shown to stimulate a-secretase-dependent APP
cleavage in astrocytoma cells [5]. In neurons, upregulation of
P2Y2Rs by interleukin-1b promotes the nucleotide-induced non-
amyloidogenic processing of APP [6], suggesting a neuroprotective
role for P2Y2 receptors in AD.
Regarding P2X receptors, it is known that the P2X7 subtype be-
comes upregulated in the brain of patients with AD and in some
transgenic mouse models of the disease [7,8]. P2X7 receptor acti-
vation induces the generation of superoxide from microglial cells
[8] and enhances cytokine secretion elicited by Ab in human mac-
rophages and microglia [9]. Moreover, neuroinﬂammatory markers
induced by exogenous administration of Ab are partially prevented
by the P2X7R antagonist brilliant blue G (BBG) [10]. These ﬁndings
suggest that P2X7 receptor could play a role in the inﬂammatory
responses seen in AD. However, little is known about the possible
role of P2X7 receptors in Ab generation. P2X7R is abundantly ex-
pressed in neurones where it seems to be targeted to axodendritic
ﬁbers and synaptic terminals [11]. Neuronal Ab release has been
linked to the synaptic activity [12]. Thus, any presynaptic receptor
able to modulate synaptic transmission has the potential to regu-
late the generation and release of Ab from neurons. Indeed, it is
well known that activation of the P2X7R leads to changes in the
activity of PKC, MAPKs or GSK3 [13], enzymes that are known for
their ability to modulate APP processing and Ab production.lsevier B.V. All rights reserved.
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nal fragments (CTFs) in Neuro-2a (N2a) cells. P2X7R induced a
reduction in the activity of a-secretase, measured by means of a-
cleaved carboxyterminal fragment of APP (a-CTF, also known as
C83) detection. Alternatively, activation of a P2Y2 receptor stimu-
lates a-secretase-mediated APP processing in the N2a cells. As both
P2X7 and P2Y2 receptors are expressed in neural cells, their capac-
ity to modulate the non-amyloidogenic APP processing suggests
that they can be novel therapeutic targets in the treatment of AD.
2. Materials and methods
2.1. Cell culture
N2a cells were plated at 8  105 cells/well in six-well plates and
cultured in DMEM (Sigma) supplemented with Glutamax
(Invitrogen), penicillin/streptomycin (Invitrogen), and 10% heat-
inactivated fetal bovine serum (EuroClone). Cells were grown at
37 C in humidiﬁed atmosphere containing 5% CO2.
2.2. RT-PCR experiments
RT-PCR analysis was performed as previously reported [14].
Brieﬂy, total RNA was extracted from cultured N2a cells and whole
adult mice brain using a Rneasy plus mini kit (Qiagen), following
the manufacturer’s instructions. After digestion with TURBO DNase
(Ambion), total RNA was quantiﬁed and reversed transcribed using
M-MLV reverse transcriptase (Invitrogen). PCRs were carried out
using AmpliTaq Gold PCRMaster Mix and speciﬁc commercial oli-
gonucleotide primers for mouse P2Y2 and P2Y4 receptors (Applied
Biosystems). Ampliﬁed PCR products were electrophoresed on a 1%
agarose gel and visualized by SYBR Safe DNA gel stain (Invitrogen).
2.3. Calcium microﬂuorimetric analysis in single cells
Microﬂuorimetric studies were performed as previously re-
ported [14]. Brieﬂy, N2a cells cultured on coverslips placed in
35 mm dishes (250 000 cells/well) were washed with Locke’s solu-
tion (composition in mM: NaCl, 140; KCl, 4.5; CaCl2, 2.5; KH2PO4,
1.2; MgSO4, 1.2; glucose, 5.5; Hepes, 10; pH 7.4), and loaded with
the calcium dye Fura-2 AM (5 lM) for 45 min at 37 C. After then,
cells were placed in a small superfusion chamber and stimulated
with a variety of purinergic receptor agonists. Cells were imaged
through a Nikon Eclipse TE-2000-E microscope using a Plan Fluor
20/0.5 lens. The incoming light was set at 340 and 380 nm.
Images were acquired with an ORCA-ER C 47 42–98 CCD camera
(Hamamatsu) controlled by Metaﬂuor 6.3r6 PC software (Universal
Imaging Corp.). Data are represented as the normalized F340/F380
ﬂuorescence ratio, which increases as [Ca2+]i increases.
2.4. Immunocytochemistry
Immunocytochemical detection of the P2Y2 receptor was car-
ried out as previously described [14]. Rabbit anti-P2Y2R (Alomone
Labs) and mouse anti-a-tubulin (Sigma) were used as primary
antibodies. Positive immunostaining was revealed using Cy3™-
conjugated donkey anti-rabbit (Jackson ImmunoResearch) and
Alexa Fluor 488 goat anti-mouse (Invitrogen) IgGs. Images were
acquired using a Leica CTR 6500 confocal microscope with a 40
immersion oil objective (NA 1.3).
2.5. Detection of APP CTFs
Cells were grown in six-well plates for 24 h to near conﬂuency
and then culture medium was removed and cells treated at 37 Cwith a range of APP secretase inhibitors or a variety of P2 receptor
agonists and antagonists (as detailed in ﬁgure legends). All the
compounds added to the cells were dissolved in Mg2+-free Locke’s
solution, prepared replacing MgSO4 by glucose at a concentration
that conserved the solution osmolarity.
Protein extracts were prepared by homogenizing the cells in
ice-cold PBS buffer, following by centrifugation at 1200 rpm for
5 min at 4 C. Supernatant was discarded and pellet was resus-
pended in 120 ll of Loading Buffer (Tris–HCl 25 mM pH 6.3, glyc-
erol 10%, SDS 10%, b-mercaptoethanol 5%, bromophenol blue
0.01%). Fifty microliters of the protein extracts (containing
45 lg of protein) were electrophoresed on 16.5% Tris–Tricine–
PAGE gels and transferred to nitrocellulose membranes (What-
man). Experiments were performed using anti-APP CTF 8717
(1:1000) and monoclonal anti-a-tubulin (1:10 000) obtained from
Sigma. A secondary goat anti-mouse (1:5000) or goat anti-rabbit
(1:1000) antibody (Dako Cytomation) was used followed by en-
hanced chemoluminescence (ECL) detection (Perkin Elmer).
2.6. P2X7 receptor knockdown
P2X7 receptor knockdownwas achieved by RNA interference, as
previously described [15]. N2a cells were plated at 6  106 cells/P-
100 dish and transiently transfected with the vector constructs
using Lipofectamine™ 2000 (Life Technologies) following the man-
ufacturer’s instructions. After 6 h, the medium was removed and
cells were further incubated in culture medium. Twenty-four hours
after the transfection, cells were plated at 8  105 cells/well in six-
well plates and maintained for another 24 h before any treatment
with the P2 receptor agonists and antagonists was done.
2.7. Western blot quantiﬁcation of P2X7R
The levels of the P2X7 receptor were quantiﬁed in cell lysates
by Western blotting. Fifty microliters of the cell lysates (45 lg
of protein) were electrophoresed on 7.5% Tris–glycine–SDS gels
and transferred to nitrocellulose membranes (Whatman). Antibod-
ies used were: rabbit anti-P2X7R intracellular epitope (1:250) from
Alomone Labs and mouse anti-a-tubulin (1:10 000) from Sigma.
Protein bands were detected by using secondary goat anti-mouse
(1:5000) or goat anti-rabbit (1:1000) antibodies (Dako Cytoma-
tion) followed by ECL detection (Perkin Elmer).
2.8. Cell viability assays
Cell viability was assessed by the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) assay. This method
employs MTT tetrasodium salt, which is reduced to a colored
formazan only by metabolically active viable cells. After the treat-
ment with the different P2 agonists or antagonists, MTT tetrasodi-
um salt (Sigma) was added to the cells at a ﬁnal concentration of
0.5 mg/ml and was maintained for 2 h at 37 C. Then, an equal
volume of MTT solubilization solution (10% Triton X-100 plus
0.1 N HCl in anhydrous isopropanol) was added, following incuba-
tion for 1 h at room temperature with orbital shaking. The samples
were collected and measured spectrophotometrically at 570 nm.
Values were normalized with respect to that obtained from
untreated cells, considered as 100% survival.
2.9. Statistical analysis
Results were analyzed by unpaired t-test using GraphPad Prism
5 (Graph Pad Software Inc.) and expressed as the mean ± standard
error of the mean (S.E.M.). Differences were considered to be sig-
niﬁcant at P 6 0.05.
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3.1. Characterization of APP CTFs in N2a cells
We reasoned that APP CTFs would provide a sensitive read-out
to study secretase dependent regulation of APP processing since
they are generated in cells directly after cleavage of APP by a-secre-
tase or b-secretase [1]. First, we characterized the pattern of APP
CTFs in N2a cells by immunoblotting using a commercially avail-
able C-terminally directed APP antibody. We only observed one
band that ran at the correct molecular weight of APP CTFs
(Fig. 1A), which range in size from 8 to 14 kDa. As it has been
shown that N2a cells process APP more via the alpha pathway, it
is likely that this band correspond with the C83 a-CTF. However,
to be certain that the band we were observing is bona ﬁde
a-cleaved APP C83, we carried out additional experiments. Treat-
ment of the cells with the broad-spectrum a-secretase inhibitor
N-(R)-[2-(hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-
naphthylalanyl-L-alanine 2-aminoethyl amide (TAPI-1)
signiﬁcantly reduced the immunoreactive band detected
(Fig. 1A). A similar result was obtained when cells were treated
with the non-selective inhibitor of metalloproteinases, N-[(2R)-
2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-trypto-
phan methylamide (GM6001). In contrast, treatment of the cells
with the b-secretase (BACE1) inhibitor IV did not induce any
reduction in the levels of the observed band but, instead, a
marked increase was obtained (Fig. 1A). These data conﬁrmed
that the APP-immunoreactive band detected was C83 CTF gener-
ated from a-secretase activity.
3.2. Inhibition of a-secretase activity by a P2X7 receptor
We performed experiments to determine whether application
of the P2X7 agonist 20(30)-O-(4-benzoylbenzoyl) ATP (BzATP) mod-
iﬁed the levels of C83 a-CTF. BzATP (100 lM) decreased the levels
of C83 after 2 and 4 h of incubation, although the reduction was
only statistically signiﬁcant after 4 h of treatment with the
nucleotide analog (Fig. 1B). To assess whether our observed
BzATP-evoked decrease in C83 levels was due to stimulation of a
P2X7-type receptor, we treated N2a cells with BzATP in the ab-
sence or in the presence of the P2X7 antagonist BBG. One micro-
molar BBG completely reverted the inhibitory effect of BzATP
(Fig. 1B), thus strongly suggesting that the observed BzATP-
induced decrease in C83 levels was mediated trough a P2X7 recep-
tor. Moreover, our measured changes in C83 levels cannot be
attributable to any cytotoxic effect caused by the prolonged
exposition to the drugs used, as neither BzATP nor BBG modiﬁed
cell viability, after 4 h of treatment, when assayed by the MTT
method (Fig. 1C).
3.3. Biphasic effect of BzATP on a-secretase activity in N2a cells
Next, we challenged N2a cells with different concentrations of
BzATP. Based in our previous data of the time course experiments,
4 h were chosen as the incubation time to routinely carry out the
experiments. When assayed in a range of different concentrations,
BzATP showed a biphasic effect: low concentrations of BzATP, up to
100 lM, induced a reduction in the detected amounts of C83 a-
CTF, while higher concentrations of the nucleotide increased a-
secretase activity (Fig. 2A). These results suggest that BzATP may
be interacting with two different nucleotide receptors to modify
a-secretase activity.
As the inhibitory effect of 100 lM BzATP could be reverted by
1 lM BBG, we repeated the dose–response curve for BzATP in the
presence of this P2X7 antagonist. BBG completely prevented theinhibitory effect of BzATP on a-secretase activity, whereas the
stimulatory component observed at higher BzATP doses was unaf-
fected by the presence of the antagonist (Fig. 2B). These results
support our previous assumption that BzATP inhibits a-secretase
activity through its interaction with a P2X7 receptor. The stimula-
tory effects of BzATP on a-secretase activity, however, seem to be
mediated through a different receptor, which is resistant to BBG.
P2X7 receptor has been show to be rather insensitive to suramin
[16], a non-selective antagonist able to inhibit most of the P2 recep-
tor subtypes [16,17]. When assayed in the presence of 100 lM sur-
amin, BzATP did not show any stimulatory effect on a-secretase
activity, but a reduction in themeasured levels of C83a-CTFwas ob-
served at any of the concentrations assayed (Fig. 2C).
As a summary, these results clearly demonstrated that BzATP,
depending on its concentration, can activate two different nucleo-
tide receptors in N2a cells. These receptors can be pharmacologi-
cally differentiated and have opposite effects on a-secretase
activity. One of them, that predominates at the lower BzATP con-
centrations and which activation leads to a reduction in a-secre-
tase activity, is inhibited by BBG, although it has been proved to
be resistant to 100 lM suramin. These results clearly point to a
P2X7 receptor as the responsible of the BzATP-mediated reduction
in a-secretase activity. The other receptor, that seems to be acti-
vated at higher BzATP concentrations and which effect is to in-
crease a-secretase activity, shows a completely different pattern
of inhibition, being insensitive to BBG and inhibited by suramin.
3.4. P2X7R knockdown prevents the inhibitory effect of BzATP on a-
secretase activity
A pSUPER.neo.gfp vector-derived small hairpin RNA (shRNA)
strategy was designed to knock down native P2X7 receptor expres-
sion. Transfection of N2a cells with a vector carrying the RNA inter-
ference for P2X7 (shRNA-P2X7), speciﬁcally reduced the
expression of the P2X7R protein when compared with control cells,
which were transfected with non-speciﬁc shRNA-luciferase vector
(shRNA-Luc) (Fig. 3A). Next, we analyze the effect of BzATP on C83
a-CTF levels in both shRNA-P2X7 and shRNA-Luc transfected cells
(Fig. 3B). Experiments were carried out in the presence of 100 lM
suramin to reduce the contribution of the a-secretase activity
enhancing receptor. A biphasic curve for BzATP was obtained in
control cells (shRNA-Luc), this nucleotide analog being able to re-
duce a-secretase activity only at its lower concentrations (up to
100 lM). However, it is relevant to note that the inhibitory effect
of BzATP on a-secretase activity disappears when P2X7 receptor
has been knocked down, the nucleotide analog being unable to de-
crease C83 a-CTF levels in cells transfected with the shRNA-P2X7
at any of the concentrations assayed (Fig. 3B).
3.5. A P2Y2 receptor mediates the BzATP-induced increase in a-
secretase activity in N2a cells
The aforementioned results clearly demonstrated that the
inhibitory effects of BzATP on a-secretase activity are mediated
through a P2X7 receptor. However, the nature of the receptor that
is responsible for the BzATP-induced increase in a-secretase activ-
ity needs to be elucidated. Previous reports have shown that a-
secretase-dependent APP processing can be enhanced by activation
of a P2Y2 receptor [5,6]. Interestingly, P2Y2 receptors can be acti-
vated by BzATP [18] and are sensitive to the inhibition with sura-
min [17], pharmacological properties that are shared by our a-
secretase stimulating receptor. In order to analyze whether a
P2Y2 receptor could account for the BzATP-induced stimulation
of a-secretase activity in N2a cells, we carried out several experi-
mental approaches.
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Fig. 1. C83 a-CTF detection and BzATP-induced a-secretase inhibition in N2a cells. (A) Representative immunoblot of C83 a-CTF detection in N2a cells treated with TAPI-1
(10 lM), GM6001 (100 lM) or BACE inhibitor IV (10 lM). a-Tubulin was used as a loading control and the ratio C83 a-CTF/a-tubulin was calculated. Ratio values are
represented as a percentage of the ratio in untreated cells (control) that was set as a 100%. Data are the mean ± S.E.M. of four independent experiments. ⁄⁄⁄P < 0.001. (B) Cells
were treated with BBG (1 lM), BzATP (100 lM) or BzATP (100 lM) in the presence of BBG (1 lM). C83 a-CTF and a-tubulin were quantiﬁed by Western blotting after
different incubation times. Representative immunoblots of C83 a-CTF and a-tubulin detection at the different treatment times are shown. Histogram represents
mean ± S.E.M. of C83 a-CTF/a-tubulin ratios normalized with respect to the control (n = 4). ⁄P < 0.05. (C) N2a cells were incubated with BzATP (100 lM) or BBG (1 lM) and
cell viability was analyzed, after 4 h of treatment, by the MTT assay. Data are the mean ± S.E.M. of three experiments performed in triplicate.
2258 M. León-Otegui et al. / FEBS Letters 585 (2011) 2255–2262First, we analyzed the calcium responses when cells were
stimulated with different nucleotide agonists that are known to
activate P2Y2 receptors. As it can be observed in Fig. 4A, equal
(100 lM) concentrations of UTP and ATP evoked similar [Ca2+]iincreases in N2a cells, UDP giving rise to responses of much less
amplitude. N2a cells also showed transient [Ca2+]i increases upon
application of 100 lM Up4U, this pattern of responses being
compatible with the presence of a functional P2Y2 receptor
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tors, such as the P2Y6, can be ruled out, as P2Y6 is a nucleosidediphosphate preferring receptor with UDP being a much more
potent agonist than UTP [17]. However, on the basis of this
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P2Y4 receptor, as this receptor has proved to be sensitive to
Up4U [19], its mouse ortholog being equipotently activated by
ATP and UTP [17].
In order to elucidate whether P2Y2 and/or P2Y4 receptors are
present in N2a cells, we analyzed the expression of both nucleotide
receptors at the transcriptional level. RT-PCR analysis demon-
strated that only P2Y2 receptors are expressed at a measurable le-
vel in N2a cells (Fig. 4B). Immunocytochemical assays conﬁrmed
the presence of P2Y2 receptors in these cells (Fig. 4C).
Once we have established the presence of a functional P2Y2
receptor in N2a cells we wonder whether the activation of such
receptor could lead to increases in a-secretase activity. Stimulation
of the cells with the P2Y2 agonist Up4U increased the levels of C83
a-CTF in a dose dependent manner (pEC50, 6.96 ± 0.20; nH,
0.96 ± 0.38), reaching saturation at 1.0 lM of added ligand
(Fig. 4D). Indeed, Up4U responses were inhibited by suramin
(Fig. 4E), which is also a pharmacological characteristic of the
P2Y2 receptor. Treatment of N2a cells with Up4U (even at the high-er concentration used, 100 lM) or suramin (100 lM) did not mod-
iﬁed cell viability, which was assessed by the MTT method (Fig. 4F).
From these data it seem reasonable to conclude that the in-
creases in a-secretase activity observed at high (>100 lM) BzATP
concentrations are mediated through the P2Y2 receptor, as BzATP
has been previously described as an activator of this type of recep-
tor [18] and these BzATP responses were also reduced in the pres-
ence of suramin (Fig. 2 A and C).
4. Concluding remarks
Identifying receptors capable of modulating the processing of
APP is an important goal, which could open new perspectives
for the treatment of AD. Up to now, inhibitors of b- and c-secre-
tases have been the focus of intense research. However, the side
effects associated to the decrease in BACE1 and c-secretase activ-
ities have restricted this therapy. Modulation of a-secretase activ-
ity could represent an alternative approach for the therapeutical
treatment of AD. It has been previously shown that activation
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Fig. 4. P2Y2 receptor increases a-secretase activity in N2a cells. (A) Intracellular calcium increments evoked by 30 s stimulation with different nucleotide agonists in N2a
cells. Traces represent mean ± S.E.M. from 156 individual cells. (B) Expression of P2Y2 and P2Y4 receptors was analyzed by RT-PCR in both N2a cells, N, and adult whole mouse
brain mRNA extracts, B, H2O, control carried out without template. M, DNA ladder. (C) Immunocytochemical detection of P2Y2 receptors in N2a cells (red). Cell morphology
was deﬁned using anti-a-tubulin antibodies (green). Scale bar, 5 lm. (D) N2a cells were stimulated with several Up4U concentrations, ranging from 1 nM to 100 lM. C83 a-
CTF and a-tubulin levels were quantiﬁed after 4 h of treatment with the P2Y2 agonist. Histogram represents the mean ± S.E.M. of C83 a-CTF/a-tubulin ratios normalized with
respect to the control (n = 5). ⁄P < 0.05; ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001. (E) Cells were preincubated for 30 min with 100 lM suramin and then stimulated with the same Up4U
concentrations used in (D), but in the presence of the antagonist. Results obtained at 1 lM Up4U are shown. Histogram represents the mean ± S.E.M. of C83 a-CTF/a-tubulin
ratios normalized with respect to the control (n = 4). ⁄⁄P < 0.01, control vs 1 lM Up4U; ##P < 0.01, 1 lM Up4U vs 1 lM Up4U + 100 lM suramin. (F) N2a cells were incubated
with Up4U (100 lM) or suramin (100 lM) and cell viability was analyzed, after 4 h of treatment, by the MTT assay. Data are the mean ± S.E.M. of three experiments performed
in triplicate.
M. León-Otegui et al. / FEBS Letters 585 (2011) 2255–2262 2261of the P2Y2 nucleotide receptor enhances a-secretase-dependent
APP processing in astrocytoma cells and primary cortical neurons
[5,6]. Our results conﬁrm the stimulatory effect of P2Y2 receptors
on a-secretase activity and support a putative role for these
receptors in AD.More interestingly, we have shown that BzATP stimulation of
the P2X7R leads to a reduction of a-secretase activity in N2a cells.
Several lines of evidence demonstrate that BzATP-mediated a-
secretase inhibition is speciﬁcally dependent on P2X7R: both the
pharmacological blockade of the P2X7 receptor and the inhibition
2262 M. León-Otegui et al. / FEBS Letters 585 (2011) 2255–2262of P2X7R synthesis by RNA interference, completely prevent the
inhibitory effect of BzATP on a-secretase activity.
While this manuscript was in preparation, a work by Delarasse
et al. [20] appeared describing an opposite effect of P2X7 on a-
secretase activity. However, it is relevant to note that our data sup-
port a neuroprotective role of P2X7 antagonism in AD, which has
been previously described in the literature [10]. P2X7 induces
the release of proinﬂammatory mediators from macrophages and
microglia [8,9] and the neuroprotective effect of P2X7 blockade
has been linked with a reduction in the levels of such inﬂammatory
molecules. Our data suggest that blocking of the P2X7 receptor
could be also beneﬁcial by enhancing the non-amyloidogenic pro-
cessing of APP, thus leading to a reduction in the generation of the
neurotoxic Ab.
In summary, this study provides the ﬁrst evidence that non-
amyloidogenic processing of APP can be regulated by two different
nucleotide receptors with opposite effects on a-secretase activity.
Because both P2X7 and P2Y2 receptors are widely expressed in
the brain, these ﬁndings could open new challenging perspectives
on the therapeutic treatment of AD. I.e. the use of activators of the
P2Y2 receptor in combination with P2X7R blockers could have ben-
eﬁcial effects by reducing the amyloid plaques.
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